Chronic kidney disease and lipoprotein (a) levels in the Russian cohort.

BACKGROUND. Lipoprotein(a) [Lp(a)] is a subclass of lipoproteins representing LDL with a single molecule of apolipoprotein B100 covalently bound to the protein apoliprotein (a). The concentration of lp(a) is determined by genetic and significant individual fluctuations (from <1 to >200 mg/dl) in the population. While the adverse effects of LP(a) on cardiovascular diseases have been proven by numerous studies, the results of studies aimed at assessing the relationship between lp(a) and CKD are contradictory. Lp(a) has not yet been included in current guidelines or public health policies for the prevention, detection, management or surveillance of CKD. 

THE AIM. To study the role of Lp(a) as a potential biomarker of CKD. 

PATIENTS AND METHODS . A retrospective single-center study was conducted with the participation of 170 patients from the Hadassah Medical Moscow clinic, divided into groups according to Lp(a) levels (<30 mg/dl, 30-50 mg/dl, >50 mg/dl). Renal function parameters (GFR, creatinine, albumin, uric acid), lipid profile, anamnestic data, and the presence of atherosclerosis were analyzed. Statistical analysis performed using Excel and Python. 

RESULTS . There were no significant differences in renal function between the groups with different Lp(a) levels. A weak negative correlation was found between Lp(a) and GFR (r = –0.11, p = 0.147), which did not reach significance. The level of Lp(a) had no effect on the lipid profile (LDL, HDL, cholesterol, triacylglycerol). 

CONCLUSIONS. Lp(a) has no significant effect on kidney function in the studied population. Further multicenter studies with a larger sample are needed to confirm the results.

1. Civic Chamber of the Russian Federation. Resolution of the round table "Modern approaches to organizing dispensary observation and statistical recording of patients with chronic kidney disease." December 6, 2023. URL: https://nephroliga.ru/upload/docs/resolution_6.12.23.pdf

2. Pyatchenkov MO, Rumyantsev ASh, Zakharov MV, Shcherbakov EV, Belskykh AN. Lipoprotein(a) and kidney diseases. Nephrology (Saint-Petersburg) 2021;25(1):31–46. (In Russ.) doi: 10.24884/1561-6274-2021-25-1-31-46. URL: https://journal. nephrolog.ru/jour/article/view/1929

3. Tsygankova OV, Bondareva KI, Latyntseva LD, Starichkova AA. Clinical and pathophysiological role of lipoprotein (a) in the development of diseases associated with atherosclerosis. RMJ 2020;12:4–8. (In Russ.)

4. Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet 2022;13:905941. doi: 10.3389/fgene.2022.905941

5. Kamstrup PR. Lipoprotein(a) and ischemic heart disease–a causal association? A review. Atherosclerosis 2010;211(1):15–23. doi: 10.1016/j.atherosclerosis.2009.12.036

6. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022;102(5S):S1–S127. doi: 10.1016/j.kint.2022.06.008

7. Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol 2014;18:234237. doi: 10.1007/s10157-013-0875-8

8. Hervio L, Girard-Globa A, Durlach V, Anglés-Cano E. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 1996;26:411–417. doi: 10.1046/j.1365-2362.1996.156288.x

9. Xuan L, Wang T, Dai H, Wang B, Xiang J, Wang S, Lin H, Li M, Zhao Z, Lu J, Chen Y, Xu Y, Wang W, Xu M, Bi Y, Ning G. Serum lipoprotein(a) associates with a higher risk of reduced renal function: a prospective investigation. J Lipid Res 2020;61(10):13201327. doi: 10.1194/jlr.RA120000771

10. Tada H, Yamagami K, Nishikawa T, Yoshida T, Teramoto R, Sakata K, Takamura M, Kawashiri MA. Lipoprotein(a) and the Risk of Chronic Kidney Disease in Hospitalized Japanese Patients. Intern Med 2020;59(14):1705–1710. doi: 10.2169/internalmedicine.4503-20

11. Xie Y, Qi H, Li B et al. Serum lipoprotein(a) associates with the risk of renal function damage in the CHCN-BTH Study: crosssectional and Mendelian randomization analyses. Front Endocrinol 2022;13:1023919. doi: 10.3389/fendo.2022.1023919

12. Liu Y, Wang R, Li S, Zhang C, Lip GYH, Thabane L, Li G. Relationship Between Lipoprotein(a), Renal Function Indicators, and Chronic Kidney Disease: Evidence From a Large Prospective Cohort Study. JMIR Public Health Surveill 2024;10:e50415. doi: 10.2196/50415

13. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43(39):3925–3946. doi: 10.1093/eurheartj/ehac361

14. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Russian Journal of Cardiology 2022;27(7):5155. (In Russ.) doi: 10.15829/1560-4071-2022-5155